Korro Bio (NASDAQ:KRRO) Stock, Quote.Headers.trade-ideas

Korro Bio

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.

Stock market analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

ALAB

ENGN

INGM

KRRO

This TechnipFMC Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Newark,,Nj,-15,Sep,2017-,Planes,From,United,Airlines,(ua)

Intraday Update

Movers

AMPS

ASPN

OKLO

United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday

Biotech

Earnings

Large Cap

Health Care

Price Target

Offerings

Small Cap

Federal Reserve

Tech

General

ASML

AVGO

IFNNF

U.S. stocks reacted positively following the Federal Open Market Committee&#39;s announcement in mid-September that it would lower interest rates by 50 basis points, wider than many analysts had anticipated.

3 Stocks That Could Rise on European Bank Interest Rate Cuts

Korro Bio Inc

The CNN Money Fear and Greed index showed some improvement in the overall market sentiment, while the index remained in the &#8220;Fear&#8221; zone on Tuesday.
U.S. stocks settled higher on Tuesday, with the Dow Jones index gaining more than 100 points during the session despite escalating geopolitical tensions and trade uncertainties between the world's two largest economies.
China responded to President Donald Trump‘s 10% import tariff with targeted countermeasures, including restrictions on key mineral exports to the U.S. and tariffs on American energy products.
Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) shares gained more than 13% on Tuesday after the company reported better-than-expected fiscal fourth-quarter 2024 financial results. Shares of Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) jumped 24% after the company reported better-than-expected financial results for the fourth quarter.
On the economic data front, U.S. job openings declined by 556,000 to 7.6 million in December, compared to market estimates of 8.0 million. U.S. factory orders fell by 0.9% from the previous month to $578.5 billion in December, compared to a revised 0.8% decline in the previous month.
Most sectors on the S&amp;P 500 closed on a positive note, with energy, information technology, and communication services stocks recording gains on Tuesday. However, utilities and consumer staples stocks bucked the overall market trend, closing the session lower.
The Dow Jones closed higher by around 134 points to 44,556.04 on Tuesday. The S&amp;P 500 rose 0.72% to 6,037.88, while the Nasdaq Composite climbed 1.35% at 19,654.02 during Tuesday's session.
Investors are awaiting earnings results from The Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), and Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) today.
What is CNN Business Fear &amp; Greed Index?
At a current reading of 39, the index remained in the &#8220;Fear&#8221; zone on Tuesday, versus a prior reading of 36.7.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>
Photo courtesy: Shutterstock

PLTR

SPOT

UBER

Nasdaq Jumps Over 1% Despite China's Trade Concerns As Palantir, Spotify Surge: Greed Index Remains In 'Fear' Zone

Uber Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) will release its fourth-quarter financial results before the <a href="https://www.benzinga.com/quote/uber/earnings">opening bell on Wednesday, Feb. 5.</a>
Analysts expect the San Francisco, California-based company to report quarterly earnings at 50 cents per share, down from 66 cents per share in the year-ago period. Uber projects quarterly revenue of $11.77 billion, compared to $9.94 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Uber&#8217;s gross bookings grew by 16% to $40.97 billion in the third quarter, though this growth rate was slower than the previous year. The company reported 161 million users in the third quarter, up 13.4% year-over-year.
Uber shares gained 3.7% to close at $69.75 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/UBER/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>UBS analyst Lloyd Walmsley maintained a Buy rating and cut the price target from $114 to $107 on Feb. 3, 2025. This analyst has an accuracy rate of 85%.</li>
<li>JMP Securities analyst Andrew Boone reiterated a Market Perform rating on Jan. 31, 2025. This analyst has an accuracy rate of 82%.</li>
<li>Benchmark analyst Daniel Kurnos reiterated a Hold rating on Jan. 31, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Cantor Fitzgerald analyst Deepak Mathivanan maintained an Overweight rating and boosted the price target from $75 to $80 on Jan. 28, 2025. This analyst has an accuracy rate of 80%.</li>
<li>Piper Sandler analyst Thomas Champion maintained an Overweight rating and cut the price target from $98 to $82 on Jan. 28, 2025. This analyst has an accuracy rate of 69%.</li>
</ul>
Considering buying UBER stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="627" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05023823/image-34-1024x627.png" alt="" class="wp-image-766377" style="width:609px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05023823/image-34-1024x627.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05023823/image-34-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05023823/image-34-768x470.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/05023823/image-34.png 1086w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>

Uber Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

KDDIY

KDDI Q3 Sales $9.90B Down From $10.06B YoY, Profit Attributable To Owners $1.22B Up From $1.16B YoY

PFSI

Reported Earlier, PennyMac Mortgage Investment Trust Prices $150M Public Offering Of 9.00% Senior Notes Due 2030

IPOs

KFIIU

Reported Earlier, K&F Growth Acquisition Corp. II Prices $250M Initial Public Offering Of 25M Units At $10/Unit

The market reacted positively to Source's proposal, and at least one of TURN's large shareholders has publicly urged TURN to engage with Source.
Source remains committed to a potential merger and hopes to work constructively with TURN's Board of Directors.

TURN

Reported Earlier, Source Capital Remains Committed To Merger Despite 180 Degree Capital's Swift Rejection

The Company intends to use the net proceeds of the Offering primarily for sales support, marketing, customer expansion and general corporate purposes, including working capital

CJMB

Reported Earlier, Callan JMB Prices $5.12M Initial Public Offering Of 1.28M Common Shares At $4/Share

With U.S. stock futures trading lower this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects The Walt Disney Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) to report quarterly earnings at $1.45 per share on revenue of $24.62 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Disney shares gained 0.3% to $113.69 in after-hours trading.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) reported better-than-expected fourth-quarter earnings, while sales missed estimates. Google Cloud revenue was up 30% year-over-year to $12 billion. Alphabet shares dipped 7.3% to $192.56 in the after-hours trading session.</li>
<li>Analysts are expecting Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) to post quarterly earnings at 50 cents per share on revenue of $11.77 billion. The company will release earnings before the markets open. Uber shares gained 1.4% to $70.71 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) reported upbeat earnings and sales results for the fourth quarter after the market closed on Tuesday. The company expects first-quarter revenue of approximately $7.1 billion, plus or minus $300 million. At the midpoint, the revenue guidance represents year-over-year growth of approximately 30%. AMD shares tumbled 8.8% to $108.94 in the after-hours trading session.</li>
<li>Analysts expect Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) to post quarterly earnings at 33 cents per share on revenue of $43.25 billion after the closing bell. Ford shares fell 0.7% to $10.09 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/02/43460681/jim-cramer-says-no-to-bigbear-ai-recommends-buying-this-tech-stock">Jim Cramer Says No To BigBear.ai, Recommends Buying This Tech Stock</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

GOOG

GOOGL

Disney, Alphabet And 3 Stocks To Watch Heading Into Wednesday

<ul>
<li>For the 2025 outlook, sales growth is expected to be 16-24% at CER, and operating profit growth is expected to be 19-27% at CER. Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.</li>
</ul>

Guidance

Novo Nordisk Forecasts 2025 Sales Growth Of 16%-24% And Operating Profit Growth At CER Of 19-27%

VLCN

Reported Earlier, Volcon Announces Public Offering Of Common Stock And Warrants

Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) reported quarterly earnings of DKK6.34 per share which beat the analyst consensus estimate of DKK 5.82 by 8.93 percent. This is a 29.12 percent increase over earnings of DKK 4.91 per share from the same period last year. The company reported quarterly sales of DKK 85.683 billion which beat the analyst consensus estimate of DKK 79.730 billion by 7.47 percent. This is a 30.09 percent increase over sales of DKK 65.863 billion the same period last year.

Earnings Beats

Novo Nordisk Q4 2024 GAAP EPS DKK 6.34 Beats DKK 5.82 Estimate, Sales DKK 85.683B Beat DKK 79.730B Estimate

GHRS

Reported Earlier, GH Research Prices $150M Public Offering Of 10M Common Shares At $15/Share

The Company intends to use the proceeds from this Offering primarily for (i) contracting the managerial and operational rights of a new parking lot, (ii) product research and development, (iii) recruitment of specialized technical and operational personnel, and (iv) Working capital and general corporate matters.

HCAI

Reported Earlier, Huachen AI Parking Management Prices $6M Initial Public Offering Of 1.5M Common Shares At $4/Share

Landmark Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LARK#NASDAQ">LARK</a>) reported quarterly earnings of $0.57 per share. This is a 23.91 percent increase over earnings of $0.46 per share from the same period last year. The company reported $15.80 million in sales this quarter. This is a 20.24 percent increase over sales of $13.14 million the same period last year.

LARK

Landmark Bancorp Q4 EPS $0.57 Up From $0.46 YoY, Sales $15.80M Up From $13.14M YoY

The UK approval marks the fourth regulatory approval Valneva has received for its single-shot chikungunya vaccine. The vaccine is currently approved in the United States (U.S.)2, Europe3 and Canada4 in adults 18 years of age and older. Valneva expects to receive marketing approval in Brazil in the first quarter of 2025, which would represent the first approval in an endemic country. Valneva submitted label extension applications to the U.S. Food and Drug Administration (FDA)5, the European Medicines Agency (EMA) and Health Canada6 to potentially extend the use of IXCHIQ&#xAE; to adolescents aged 12 to 17 years. The Company now also plans to submit a label extension application to MHRA.

VALN

Valneva's Chikungunya Vaccine IXCHIQ Gains UK Regulatory Approval, Expanding Global Access

Outlook&nbsp;
• Organic capital expenditures&#x2A; are estimated at USD 13 billion for 2025 .&nbsp;
• Oil &amp; gas production for 2025 is estimated to grow 4% compared to 2024 level.&nbsp;
• Equinor's ambition is to keep the unit of production cost in the top quartile of its peer group. • Scheduled maintenance activity is estimated to reduce equity production by around 30 mboe per day for the full year of 2025.

EQNR

Equinor Estimates $13B Capital Expenditure For 2025, Forecasts 4% Oil & Gas Production Growth

The board of directors proposes to the annual general meeting an ordinary cash dividend of USD 0.37 per share for the fourth quarter 2024, an increase of USD 0.02 per share from the third quarter of 2024, in line with previously announced ambition. The Equinor share will trade ex-dividend on Oslo Børs from and including 15 May and New York Stock Exchange from and including 16 May 2025.

Dividends

Equinor Proposes Q4 Dividend Increase To $0.37 Per Share, Up $0.02 From Prior Quarter, Payable May 28

In this first tranche, shares for up to USD 396 million will be purchased in the market, implying a total first tranche of up to USD 1.2 billion including shares to be redeemed from the Norwegian State. The tranche will end no later than 2 April 2025.
Equinor announces a share buy-back programme of up to USD 5 billion for 2025, including shares to be redeemed from the Norwegian State, in order to conclude the two-year programme for 2024 – 2025, announced in February 2024.

Buybacks

Equinor Kicks Off $5B Share Repurchase Plan With Initial $1.2B Tranche Set For April 2025 Completion

Equinor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.62 by 1.61 percent. This is a 0.63 percent decrease over earnings of $0.63 per share from the same period last year. The company reported quarterly sales of $26.418 billion which beat the analyst consensus estimate of $25.973 billion by 1.71 percent. This is a 7.25 percent decrease over sales of $28.483 billion the same period last year.

Equinor Q4 2024 Adj. EPS $0.63 Beats $0.62 Estimate, Sales $26.418B Beat $25.973B Estimate

The XRP Ledger (XRPL), the blockchain network that powers XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>), experienced an unprecedented hour-long interruption in block production on Tuesday before spontaneously recovering, according to Ripple&#8216;s Chief Technology Officer David Schwartz.
What Happened: &#8220;The network is now recovering. We don&#8217;t know exactly what caused the issue yet,&#8221; Schwartz posted on X. He suggested the disruption might have stemmed from a &#8220;silent network&#8221; failure mode, where validators stopped publishing validations while consensus mechanisms continued running.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The network is now recovering. We don&#39;t know exactly what caused the issue yet. Super-preliminary observation: It looked like consensus was running but validations were not being published, causing the network to drift apart. Validator operators manually intervened to choose a…
&mdash; David &quot;JoelKatz&quot; Schwartz (@JoelKatz) <a href="https://twitter.com/JoelKatz/status/1886914174565146852?ref_src=twsrc%5Etfw">February 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The incident marks a notable disruption for the XRP Ledger, which has processed over 70 million ledgers since its 2012 launch. During the outage, no validated ledgers were lost, though tentative ledgers were discarded as part of normal protocol operations.
The XRP Ledger&#8217;s unique Federated Consensus mechanism, which relies on over 150 independent validators worldwide, played a key role in the recovery. Some validator operators manually intervened to establish a new starting point after the last fully validated ledger, though Schwartz noted that &#8220;very few UNL operators actually made any changes.&#8221;
See Also: <a href="https://www.benzinga.com/markets/commodities/25/02/43485292/gold-outshines-bitcoin-as-trumps-gaza-plan-us-china-tensions-fuel-rally-peter-schiff-calls-it-extremely-bullish">Gold Outshines Bitcoin As Trump&#8217;s Gaza Plan, US-China Tensions Fuel Rally—Peter Schiff Calls It &#8216;Extremely Bullish&#8217;</a>
Why It Matters: This disruption comes as particularly significant given XRPL&#8217;s reputation for reliability and its growing importance in various financial applications. The network, known for processing 1,500 transactions per second with 3-5 second settlement times, has become integral to payments, tokenization, DeFi, and CBDC initiatives.
For investors, while the incident highlights potential vulnerabilities in distributed ledger systems, the network&#8217;s swift recovery and built-in safety mechanisms demonstrated its resilience. No user funds were affected during the interruption, as the system&#8217;s safety protocols prevented the acceptance of unverified transactions. &#8220;This is the &#8220;silent network&#8221; failure,&#8221; Schwartz said. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One possible failure mode for XRPL is if all the validators think something&#39;s wrong with the network, all refuse to send any validations, and then there&#39;s no chatter to let the network reconverge. This is the &quot;silent network&quot; failure. XRPL has safeties both to prevent and…
&mdash; David &quot;JoelKatz&quot; Schwartz (@JoelKatz) <a href="https://twitter.com/JoelKatz/status/1886965687555645873?ref_src=twsrc%5Etfw">February 5, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The development team continues to investigate the root cause of the disruption, with Schwartz emphasizing the preliminary nature of current observations.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43484922/bitcoin-ethereum-dogecoin-drops-as-trumps-crypto-czar-announces-oversight-committee-eric-trump-says-great-time-to-add-eth">Bitcoin, Ethereum, Dogecoin Drops As Trump&#8217;s &#8216;Crypto Czar&#8217; Announces Oversight Committee: Eric Trump Says &#8216;Great Time&#8217; To Add ETH</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$XRP

XRP Ledger Suffers Hour-Long Outage Before Recovery: Ripple CTO Says 'Silent Network' Failure Didn't Impact User Funds

Press Releases

Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates

Korro to Present at the Jefferies London Healthcare Conference

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Korro to Participate in Upcoming Investor Conferences

Management

CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors

Korro to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency and Provides Pipeline Update

Comments

Korro Bio

Korro Bio (KRRO) Forecast

Korro Bio (NASDAQ:KRRO) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga